B
Bullisch
Bullisch · 25%DNA
$11.62
Szenariopreis
$10.270
-1.301 (-12.67%)Zum Schluss
Loading chart…
- Hoch
- 11.800
- Eröffnung
- 11.620
- Volumengewichteter Durchschnittskurs
- 10.73
- Volumen
- 3.55M
- Marktkap.
- 683.73M
- Tief
- 10.125
- Umsatz
- 38.15M
- EV/EBITDA, TTM
- -5.03
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering.
KI-Analyse of Ginkgo Bioworks Holdings Inc (DNA)
VerkaufenGinkgo Bioworks is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $10.27, and the company reported a staggering 21% decline over the last five days. Additionally, the RSI is at 35.487, indicating oversold conditions but also reflecting weak momentum. The recent downgrade by TD Cowen, coupled with insider selling increasing by 74248.78%, suggests a lack of confidence in the company's near-term growth prospects, making it a risky investment at this time.
Analystenbewertungen (2)
+16.85% Aufwärtspotenzial
Verkaufen
0 Kaufen
0 Halten
2 Verkaufen
Aktuell: 10.27
Tief
12.00
Durchschnitt
12.00
Hoch
12.00
TD Cowen
Halten
$9
2026-08-07
TD Cowen
2026-08-07
Kursziel
$9
Halten
BTIG
Verkaufen
$5
2026-03-12
BTIG
2026-03-12
Kursziel
$5
Verkaufen
TD Cowen
Kaufen
$12
2026-01-08
TD Cowen
2026-01-08
Kursziel
$12
Kaufen
BTIG
Verkaufen
$9
2025-08-25
BTIG
2025-08-25
Kursziel
$9
Verkaufen
TD Cowen
Kaufen
$16
2025-08-08
TD Cowen
2025-08-08
Kursziel
$16
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Ginkgo Bioworks Holdings Inc (DNA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -6.73.
Alphio-AI-Kursszenarien für DNA
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die DNA halten
Event-Zeitleiste
News
7.510-09PRnewswireGinkgo Integrates Araceli's High-Throughput Imaging Technology
7.510-08NewsfilterGinkgo Bioworks Supports NSF X-Labs Program with Autonomous Lab Access
7.510-08PRnewswireGinkgo Bioworks Integrates Araceli's High-Throughput Imaging Technology
7.510-08PRnewswireAraceli and Ginkgo Enhance Cellular Imaging Capabilities
7.510-08PRnewswireGinkgo Integrates Araceli's Endeavor for Enhanced Cellular Data Generation
DNA FAQ – beantwortet von Alphio AI
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Ginkgo Bioworks is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $10.27, and the company reported a staggering 21% decline over the last five days. Additionally, the RSI is at 35.487, indicating oversold conditions but also reflecting weak momentum. The recent downgrade by TD Cowen, coupled with insider selling increasing by 74248.78%, suggests a lack of confidence in the company's near-term growth prospects, making it a risky investment at this time.
2 analysts cover DNA: 0 rate it Buy, 0 Hold and 2 Sell. The average price target is 12.00.
Community
Mehr ↗
$ETH $DNA $XRP One of the biggest steps I’ve taken toward building my future has been learning about crypto market insights and copy trading approaches. The profits I’ve made along the way have helped me put money toward something truly meaningful: starting my own house project. Seeing the foundation take shape makes the progress feel real, and it reminds me why I started investing in the first place. What stood out to me was the value of having a clearer trading strategy, understanding market movements, and making more informed decisions instead of relying on guesswork. I’m genuinely pleased with how far I’ve come, and I recommend learning from market insights to anyone looking to explore crypto trading. For me, this journey is about more than trading; it’s about turning financial progress into something lasting.
Mehr anzeigen
🚨 MARKET ANALYSIS — Crypto Movers to Watch 📊 📈 BTC/USDT: $81,985.80 | +0.57% 🟢 Bitcoin is showing a modest recovery, with buyers attempting to maintain upward momentum. Watch for stronger volume to confirm whether the move can continue. 📉 SOL/USDT: $104.08 | -0.25% 🟠 Solana is trading slightly lower, indicating mild selling pressure. A recovery may develop if buyers defend nearby support and volume improves. 🔻 DNA/USDT: $0.26 | -4.03% 🔴 DNA is under selling pressure and is the weakest performer among these three assets. Watch for stabilization and support confirmation before anticipating a rebound. 📊 Market Takeaway 🟢 BTC: Slight bullish momentum. 🟠 SOL: Near-term consolidation with mild downside pressure. 🔴 DNA: Bearish momentum; recovery needs confirmation. 🎯 Trading Focus: BTC strength could help support broader market sentiment, but confirmation is essential. Monitor volume, support levels, and resistance before entering a trade. 👀 Which one are you watching today — BTC, SOL, or DNA? Not financial advice. Always manage risk carefully. $BTC $SOL $DNA
Mehr anzeigen
$DNA failed to break above 0.32 three times and has now pushed up again to 0.29. After analyzing it, I decided to open a short. Stop loss at 0.32, take profit at 0.26.
Mehr anzeigen
$DNA long setup — buyers are returning strongly! 🚀 Entry: 0.2800 – 0.2850 (long) Stop loss: 0.2710 Take profit 1: 0.2920 Take profit 2: 0.3050 Take profit 3: 0.3170 $DNA is rebounding strongly from the 0.2535 support zone. Bulls are pushing the price higher, and a break above 0.2920 could open upside toward 0.3170. Wait for support confirmation before entering! 🔥
Mehr anzeigen
$DGAI $DNA 🔥 Buy $UMXM Large accumulation zone, start buying now 🚀🚀🚀🚀
Mehr anzeigenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.